COVID-19 vaccines reduce hospitalization risk from Delta variant by at least 90 percent, U.K. studies find


Public health officials are worried about the Delta variant of the COVID-19 coronavirus, but two U.K. studies published Monday found that two doses of leading vaccines offer "very, very substantial" protection against the new, highly transmissible strain, Aziz Sheikh, director of the University of Edinburgh's Usher Institute and lead author of one of the two studies, tells The Wall Street Journal.
One analysis by Public Health England of more than 14,000 Delta infections found that two doses of the Pfizer/BioNTech vaccine reduced the risk of hospitalization by 96 percent, while a double dose of the Oxford-AstraZeneca vaccine lowered the risk by 92 percent. The second study, published as a letter in The Lancet by academics and public health experts in Scotland, found that two doses of either vaccine reduced hospitalization from the Delta variant by 70 percent and offered robust but slightly diminished protection against infection.
The Delta variant, first seen in India, is now the dominant strain in Britain, accounting for 90 percent of new cases. Compared with previous variants, the Delta mutation appears significantly more likely to infect people who have only received one dose of the two-shot vaccines. The U.K.'s initial vaccination strategy involved getting one jab into as many arms as possible before focusing on second doses. "We've got an opportunity to counter the threat of this Delta variant by encouraging uptake of both doses of the vaccine," Jim McMenamin, national incident director for COVID-19 at Public Health Scotland, told reporters Monday.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Road trip: New England’s maple syrup season
Feature New England is serving up maple syrup in delicious and unexpected ways
By The Week US Published
-
Music Reviews: Mdou Moctar, Panda Bear, and Tate McRae
Feature “Tears of Injustice,” “Sinister Grift,” and “So Close to What”
By The Week US Published
-
What's at stake in the Mahmoud Khalil deportation fight?
Talking Points Vague accusations and First Amendment concerns
By Joel Mathis, The Week US Published
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
By Peter Weber, The Week US Published
-
Texas outbreak brings 1st US measles death since 2015
Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
By Rafi Schwartz, The Week US Published
-
Mystery illness spreading in Congo rapidly kills dozens
Speed Read The World Health Organization said 53 people have died in an outbreak that originated in a village where three children ate a bat carcass
By Peter Weber, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published